ABBV-706 is an antibody-drug conjugate targeting SEZ6 protein, showing promise in small cell lung cancer treatment. The clinical trial assesses ABBV-706's safety, tolerability, pharmacokinetics, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results